DEFC14A: Zevra Therapeutics Faces Proxy Fight as Mangless Nominates Directors

Zevra Therapeutics is urging stockholders to vote for its director nominees, Wendy Dixon and Tamara Favorito, amidst a proxy contest initiated by Daniel J. Mangless.

Summary

• Zevra Therapeutics has scheduled its 2025 Annual Meeting of Stockholders for May 29, 2025.
• The primary agenda includes the election of two Class I directors and the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Daniel J. Mangless has nominated Travis C. Mickle, Ph.D., and Arthur C. Regan as director candidates, opposing the Board's nominees, Wendy Dixon, Ph.D., and Tamara A. Favorito.
• The Board recommends voting for Wendy Dixon and Tamara Favorito using the WHITE proxy card.
• The company is using a universal proxy card, which includes both the Board's nominees and Mangless's nominees.
• Stockholders are advised to discard any blue proxy cards received from Mr. Mangless and to use the WHITE proxy card provided by the company.
• The record date for the Annual Meeting is April 4, 2025.
• The company has retained Sodali & Co to aid in the solicitation of proxies and related advisory services, for a fee of up to approximately $300,000, plus reimbursement of expenses.
• The company's expenses in connection with its solicitation of proxies, excluding normal expenses related to a non-contested solicitation of proxies and excluding salaries and wages of its officers and regular employees, are expected to aggregate to approximately $750,000.
• The deadline to submit stockholder proposals for inclusion in the next year's proxy materials is December 22, 2025.
• The deadline to submit a proposal for presentation at the Annual Meeting that is not to be included in next year's proxy materials is February 28, 2026, but no earlier than January 29, 2026.

Sentiment

Score: 6

Explanation: The document is primarily informational, but the proxy contest introduces an element of uncertainty and potential disruption, resulting in a neutral sentiment score.

Positives

• The Board is actively managing Board composition through succession planning.
• The Nominating and Corporate Governance Committee is reviewing the company's classified board structure.
• The company proactively engages with stockholders from time to time throughout the year to learn their perspectives on significant issues, and intends to continue to do so, including with respect to gathering stockholder perspectives on Board leadership structure.

Negatives

• The company is engaged in a proxy contest, which can be disruptive and costly.
• Daniel J. Mangless has nominated two opposing director candidates, leading to a proxy contest.
• The company's expenses in connection with its solicitation of proxies, excluding normal expenses related to a non-contested solicitation of proxies and excluding salaries and wages of its officers and regular employees, are expected to aggregate to approximately $750,000.

Risks

• The proxy contest could result in a change in the composition of the Board, potentially altering the company's strategic direction.
• Failure to secure a quorum at the Annual Meeting could delay important decisions.
• The company is not responsible for the accuracy of any information provided by, or relating to, Mr. Mangless or his nominees contained in any proxy solicitation materials filed or disseminated by, or on behalf of, Mr. Mangless or any other statements that Mr. Mangless may otherwise make.

Future Outlook

The company is focused on developing transformational, patient-focused therapies for rare diseases with limited or no treatment options.

Management Comments

• The Board believes that the director nominees proposed by our Board, with their breadth of relevant and diverse experience, are the most qualified candidates up for election at the Annual Meeting.
• Our Board recommends you vote FOR the Boards two nominees by submitting the enclosed WHITE proxy card.
• The Board strongly urges you to discard and NOT to sign or return any blue proxy card sent to you by Mr. Mangless.

Industry Context

The document highlights the importance of corporate governance and stockholder engagement in the biopharmaceutical industry, particularly for companies focused on rare diseases.

Comparison to Industry Standards

• The company's director compensation policy is generally in line with industry standards for similarly sized companies.
• The use of a universal proxy card is now standard practice in contested director elections, as mandated by SEC rules.
• The company's engagement of a proxy solicitor and the estimated costs associated with the proxy solicitation are typical for contested elections.

Stakeholder Impact

• The outcome of the director election will impact the composition of the Board and potentially the company's strategic direction.
• The ratification of the independent auditor is important for maintaining investor confidence.
• The proxy contest could create uncertainty for employees and other stakeholders.

Next Steps

• Stockholders need to review the proxy materials and vote using the WHITE proxy card.
• The company will continue to solicit proxies and engage with stockholders.
• The Annual Meeting will be held on May 29, 2025, and the results will be published in a Current Report on Form 8-K.

Key Dates

Keywords

proxy contest, annual meeting, board of directors, director election, proxy statement, corporate governance, stockholders, Zevra Therapeutics